Antitumour effects of Yangzheng Xiaoji in human osteosarcoma: The pivotal role of focal adhesion kinase signalling

Oncology Reports

Volumn 30, Issue 3, 2013, Pages 1405-1413

  Jiang, Wen G ^a,b   Ye, Lin ^a,b   Ji, Ke ^a,b   Ruge, Fiona ^a,b   Wu, Yiling ^c   Gao, Yong ^c   Ji, Jiafu ^a,d   Mason, Malcolm D ^a,b  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^c Yiling Medical Research Institute Tianshan Dajie   (China)

^d PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

Author keywords

Cell adhesion; Electric cell substrate impedance sensing; Focal adhesion kinase; In vivo model; Integrin; Osteosarcoma; Paxillin; Yangzheng Xiaoji

Indexed keywords

CHINESE DRUG; FAK 573228; FOCAL ADHESION KINASE; FOCAL ADHESION KINASE INHIBITOR; FP 573228; PAXILLIN; UNCLASSIFIED DRUG; YANGZHENG XIAOJI;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL ADHESION; CONTROLLED STUDY; ELECTROCHEMICAL ANALYSIS; ENZYME REPRESSION; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; OSTEOSARCOMA; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BONE NEOPLASMS; CELL ADHESION; CELL PROLIFERATION; DRUGS, CHINESE HERBAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FOCAL ADHESION KINASE 1; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, NUDE; OSTEOSARCOMA; PAXILLIN; PHOSPHORYLATION; PLANT EXTRACTS; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84880613679     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2586     Document Type: Article

References (26)

1. Mirabello L, Troisi RJ, and Savage SA: Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer 115: 1531-1543, 2009.
2. Dorfman HA and Czerniak B: Bone cancers. Cancer 75 (Suppl 1): S203-S210, 1995.
3. Hayden JB and Hoang BH: Osteosarcoma: basic science and clinical implications. Orthop Clin North Am 37: 1-7, 2006.
4. Wachtel M and Schäfer BW: Targets for cancer therapy in childhood sarcomas. Cancer Treat Rev 36: 318-327, 2010.
5. Kubo T, Piperdi S, Rosenblum J, Antonescu CR, Chen W, Kim HS, Huvos AG, Sowers R, Meyers PA, Healey JH and Gorlick R: Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer 112: 2119-2129, 2008.
6. Ferrari S and Palmerini E: Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 19: 341-346, 2007.
7. Jiang WG, Ye L, Ji K, Frewer N, Ji J and Mason MD: Inhibitory effects of Yangzheng Xiaoji on angiogenesis and the role of the focal adhesion kinase pathway. Int J Oncol 41: 1635-1642, 2012.
8. Ye L, Ji K, Frewer N, Ji J and Jiang WG: Impact of Yangzheng Xiaoji on the adhesion and migration of human cancer cells: the role of the AKT signalling pathway. Anticancer Res 32: 2537-2543, 2012.
9. Zhang SY, Gu CH, Gao XD and Wu YL: A random, double-blinded and multicentre study of chemotherapy assisted Yangzheng Xiaoji capsule on treating primary hepatic carcinoma. Chin J Diffic Compl Case 8: 461-464, 2009.
10. Wang QL, Xuo CM, Wu XP, Li YX and Bi XJ: Treatment of atypical gastric dysplasia using Yangzheng Xiaoji. Chin J Diffic Compl Case 7: 38-39, 2009.
11. Ye Li, Ji K, Ji JF, Hargest R and Jiang WG: Application of electric cell-substrate impedance sensing in evaluation of traditional medicine on the cellular functions of gastric and colorectal cancer cells. Cancer Metastasis Biol Treat 17: 195-202, 2012.
12. Jiang WG, Hiscox S, Hallett MB, Scott C, Horrobin DF and Puntis MC: Inhibition of hepatocyte growth factor-induced motility and in vitro invasion and motility of human colon cancer cells by gamma-linolenic acid. Br J Cancer 71: 744-752, 1995.
13. Giaever I and Keese CR: Micromotion of mammalian cells measured electrically. Proc Natl Acad Sci USA 88: 7896-7900, 1991.
14. Keese CR, Wegener J, Walker SR and Giaever I: Electrical wound-healing assay for cells in vitro. Proc Natl Acad Sci USA 101: 1554-1559, 2004.
15. Jiang WG, Martin TA, Lewis-Russell JM, Douglas-Jones A, Ye L and Mansel RE: Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome. Mol Cancer 7: 71, 2008.
16. Davies G, Mason MD, Martin TA, Parr C, Watkins G, Lane J, Matsumoto K, Nakamura T and Jiang WG: The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo. Int J Cancer 106: 348-354, 2003.
17. Ye L, Martin TA, Parr C, Harrison GM, Mansel RE and Jiang WG: Biphasic effects of 17-β-estradiol on expression of occludin and transendothelial resistance and paracellular permeability in human vascular endothelial cells. J Cell Physiol 196: 362-369, 2003.
18. Gilmore AP and Romer LH: Inhibition of focal adhesion kinase (FAK) signaling in focal adhesions decreases cell motility and proliferation. Mol Biol Cell 7: 1209-1224, 1996.
19. Chen JY, Tang YA, Huang SM, Juan HF, Wu LW, Sun YC, Wang SC, Wu KW, Balraj G, Chang TT, Li WS, Cheng HC and Wang YC: A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res 71: 473-483, 2011.
20. Stokes JB, Adair SJ, Slack-Davis JK, Walters DM, Tilghman RW, Hershey ED, Lowrey B, Thomas KS, Bouton AH, Hwang RF, Stelow EB, Parsons JT and Bauer TW: Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. Mol Cancer Ther 10: 2135-2145, 2011.
21. Halder J, Lin YG, Merritt WM, Spannuth WA, Nick AM, Honda T, Kamat AA, Han LY, Kim TJ, Lu C, Tari AM, Bornmann W, Fernandez A, Lopez-Berestein G and Sood AK: Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res 67: 10976-10983, 2007.
22. Infante JR, Camidge DR, Mileshkin LR, Chen EX, Hicks RJ, Rischin D, Fingert H, Pierce KJ, Xu H, Roberts WG, Shreeve SM, Burris HA and Siu LL: Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. J Clin Oncol 30: 1527-1533, 2012.
23. Soria JC, Plummer R, Ranson M, Gan H, Arkenau HT, Zalcman G, Blagden S, Evans TRJ, Peddareddigari V, Mazumdar J, Murray S, Gidson D, Fleming RA, Auger K and Millward M: Loss of the tumor suppressor merlin as a potential predictive biomarker of clinical activity for the oral, focal adhesion kinase (FAK) inhibitor GSK2256098 in pts with recurrent mesothelioma. Eur J Cancer 48 (Suppl 6): S188, 2012.
24. Ritter J and Bielack SS: Osteosarcoma. Ann Oncol 21 (Suppl 7): vii320-vii325, 2010.
25. Anninga JK, Gelderblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoorn PC and Egeler RM: Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer 47: 2431-2445, 2011
26. Jaffe N: Osteosarcoma: review of the past, impact on the future. The American experience. Cancer Treat Res 152: 239-262, 2009.